<DOC>
	<DOCNO>NCT00296933</DOCNO>
	<brief_summary>Major Depressive Disorder ( MDD ) serious illness associate considerable morbidity , risk suicide adverse social consequence ( Montgomery et al. , 1994a ) . Cognitive impairment one three major symptom area MDD . Specifically , memory impairment concern one commonly report complaint MDD . While antidepressant ( AD ) treatment vary great deal propensity cause cognitive impairment , remain paucity empirical evidence effect AD treatment neuropsychological index memory function non-geriatric depressed individual . Hence , comparative effect various AD drug memory function remain unclear.The aim study evaluate multiple aspect memory functioning ( short-term , work memory , verbal , non-verbal , spatial prospective memory ) MDD patient 8 week antidepressant treatment bupropion XL escitalopram .</brief_summary>
	<brief_title>Memory Functioning Antidepressant Treatment</brief_title>
	<detailed_description>Purpose Present Study : The purpose present study comprehensively evaluate memory function MDD patient 8 week antidepressant treatment bupropion-XL escitalopram . A neuropsychological test battery incorporate multiple aspect memory function include : short-term &amp; working memory ; verbal , non-verbal , spatial prospective memory . Major Research Questions : 1 . Which subtypes memory baseline impair ? 2 . What relationship memory impairment symptom severity previous number episode duration illness ? 3 . Is successful AD treatment associate improvement memory function ? 4 . Is main effect AD type ? 5 . On subtypes memory patient improve , worsen , remain neutral 2 different AD group ? ( Main effect memory type ? ) 6 . What relationship change memory function symptomatic outcome ? Study Design : This randomize , double-blind , double-dummy trial compare memory function depressed subject 8 week treatment bupropion-XL compare escitalopram . All consenting , eligible subject receive either active bupropion-XL active escitalopram follow baseline visit . Doses fixed opportunity dose reduction subject unable tolerate fix dose .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Males Females Age : 1850 Recurrent Major Depressive Disorder ; current Major Depressive Episode least one prior episode HAMD &gt; 16 Able give write informed consent Agree use reliable mean birth control study , determine investigator ( female childbearing potential ) History head injury loss consciousness longer 30 minute Presence primary anxiety disorder , bipolar I II disorder , psychotic disorder Presence anorexia nervosa bulimia nervosa Presence history epilepsy seizure disorder Presence significant Axis II disorder base investigator judgment Presence significant unstable medical condition Presence past history ADHD significant learn disability ECTs ( unilateral ) within past 12 month bilateral ECT ( ever ) More 2 fail adequate antidepressant treatment current episode Pregnant breastfeeding female Have receive treatment within last 30 day investigational drug Prior nonresponse either bupropionXL escitalopram Current treatment Zyban ( bupropion hydrochloride ) Antidepressant treatment within last week ( within last 3 week fluoxetine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Major Depression</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>Pharmacotherapy</keyword>
	<keyword>Memory functioning</keyword>
	<keyword>Memory Impairment</keyword>
</DOC>